| http://www.w3.org/ns/prov#value | - Without any U.S. competition --GlaxoSmithKline's (NYSE: GSK ) Synflorix is approved in Europe and some other markets -- health plans will not have much choice but to pay for it because the Centers for Disease Control and Prevention recommended using the new vaccine instead of the old one for all new immunizations yesterday.
|
